Specialties/Topics

- Cardiology
- Dermatology
- Diabetes
- Endocrinology
- Gastroenterology
- Hematology
- Infectious Diseases
- Neurology
- Oncology
- Psychiatry
- Pulmonology
- Rheumatology
- Women's Health

Customize Your Experience
Customize Now

Society for Participatory Medicine
Innovator Supporter

Download on the App Store

Multiple Sclerosis: The Advanced Curriculum

Expert Insight Into:

Subgroup Analyses of Placebo-Controlled Trial with an Oral Immunomodulator for the Treatment of RRMS (Part 2 of Series)

Based on the Article:

Relapse and Disability Outcomes in Patients with Multiple Sclerosis Treated with Fingolimod: Subgroup Analyses of the Double-Blind, Randomised, Placebo-Controlled FREEDOMS Study. Lancet Neurol. 2012;11(5):420-428.

(Course MS05.02)

Published on August 30, 2012 Article Review

Expert Faculty: Aaron E. Miller, MD
Medical Writer: Carol Gorman, MS

This CME/CE activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME/CE activities may not contain the most up-to-date information available.

Click here to view our current activities in Neurology.

Overview | Faculty

NEXT

Subgroup analyses can provide valuable insights into appropriate treatment strategies based on a patientâs baseline characteristics. Join Dr. Aaron E. Miller as he discusses the findings of subgroup analyses from a pivotal phase 3 trial for the first orally administered, disease-modifying therapy for relapsing-remitting multiple sclerosis (RRMS), and the implications of these results for the management of RRMS.

Faculty
Aaron E. Miller, MD
Professor of Neurology and Medical Director
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai School of Medicine
New York, NY

Google +

Recommend 0 Follow

NEXT

topArticle Review

2137.02

Copyright 1997-2015. Projects In Knowledge Inc. All rights reserved.
Peer Reviewed Continuing Medical Education Courses | Free CME/CE Courses & Resources
PROJECTS IN KNOWLEDGE, TX REPORTER, MEDIMAGE CASES, LIVING MEDICAL ETEXTBOOK, SHARE YOUR KNOWLEDGE, SHARE YOUR CASE, and CLINICIANS CHANNEL are registered trademarks of Projects In Knowledge, Inc.
Projects In Knowledge - 290 W. Mt. Pleasant Avenue, Suite 2350 - Livingston, New Jersey - 07039 - 973.890.8988

Get Started

Multiple Sclerosis Curricula

Step 1

Select a topic ...

This independent CME/CE activity is supported by an educational grant from **Teva Neuroscience**

TEVA Neuroscience

Additional grant support from Novartis Pharmaceuticals Corporation, Allergan, and Bayer HealthCare

NOVARTIS

ALLERGAN

Bayer HealthCare

Poll Question

In patients treated with fingolimod 0.5 mg, the greatest annualized relapse rate (ARR) reduction among subgroups defined by baseline disease characteristics is seen in which group?

- Patients who had experienced â¤1 relapse in the year before the study
- Patients who had experienced >1 relapse in the year before the study
- Patients who had a baseline Expanded Disability Status Scale (EDSS) score of 0â3.5 points
- Patients who had a baseline EDSS score of >3.5 points

Submit

RELATED ACTIVITIES

- Journal Insights into: Phase III Trial Results for an Oral Sphingosine-1 Phosphate Receptor Modulator in Patients with

RRMS

- Case Study #4: Treatment Decisions at Diagnosis and Breakthrough for Male Patients with Relapsing-Remitting MS Who Desire to Have Children
- Case Study #3: Management of Patients with Relapsing-Remitting MS and Worsening Disease on Interferon-Beta Therapy